Arvinas, Inc. balance sheet
At the end of fiscal 2025, Arvinas, Inc. had total assets of $718m, total liabilities of $284m and shareholders' equity of $434m. It held $143m in cash against $600,000 of debt: net cash of $142m.
Balance sheet
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 31 | 3 | 9 | 588 | 108 | 81 | 312 | 101 | 143 | 94 |
| Receivables | 25 | 3 | — | 1 | 15 | 1 | 0 | 6 | 1 | 50 |
| Total current assets | 66 | 196 | 291 | 703 | 1,553 | 1,240 | 1,280 | 1,067 | 701 | 652 |
| Total assets | 67 | 199 | 302 | 717 | 1,582 | 1,269 | 1,305 | 1,091 | 718 | 675 |
| Accounts payable | 1 | 3 | 5 | 7 | 31 | 6 | 18 | 13 | 24 | 8 |
| Deferred revenue (current) | 14 | 16 | 20 | 22 | 206 | 219 | 163 | 156 | 71 | 0 |
| Total current liabilities | 18 | 23 | 33 | 49 | 262 | 295 | 257 | 230 | 143 | 83 |
| Short-term debt | 0 | 0 | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 |
| Total debt | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total liabilities | 67 | 63 | 75 | 75 | 800 | 704 | 645 | 530 | 284 | 113 |
| Shareholders' equity | −61 | 137 | 227 | 642 | 782 | 565 | 660 | 562 | 434 | 562 |
| Non-controlling interests and other (assets − liabilities − equity) | 61 | — | — | — | — | — | — | — | — | — |
| Net debt (negative = net cash) | −31 | −1 | −7 | −586 | −107 | −80 | −311 | −100 | −142 | −94 |
| Shares outstanding | — | — | 38m | 49m | 53m | 53m | 68m | 69m | 64m | 65m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 7 | 6 | 0 | 1 | 20 | 1 | 2 | 50 |
| Total current assets | 1,150 | 1,067 | 980 | 890 | 826 | 701 | 631 | 652 |
| Total assets | 1,167 | 1,091 | 1,001 | 909 | 844 | 718 | 648 | 675 |
| Accounts payable | 18 | 13 | 26 | 17 | 18 | 24 | 31 | 8 |
| Deferred revenue (current) | 199 | 156 | 141 | 103 | 88 | 71 | 52 | 0 |
| Total current liabilities | 276 | 230 | 214 | 158 | 145 | 143 | 116 | 83 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Total debt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total liabilities | 581 | 530 | 341 | 300 | 280 | 284 | 261 | 113 |
| Shareholders' equity | 586 | 562 | 660 | 609 | 564 | 434 | 387 | 562 |
| Shares outstanding | 69m | 69m | 73m | 73m | 71m | 64m | 65m | 65m |
Compare with peers
- Iovance Biotherapeutics, Inc. balance sheet
- Adaptive Biotechnologies Corp balance sheet
- Vericel Corp balance sheet
- Vir Biotechnology, Inc. balance sheet
- Syndax Pharmaceuticals Inc balance sheet
Head to head: ARVN vs IOVAADPT vs ARVNARVN vs VCELARVN vs VIR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies